In yesterday’s Wall Street session, Akebia Therapeutics Inc. (NASDAQ:AKBA) shares traded at $0.99, up 6.98% from the previous session.
AKBA stock price is now -16.36% away from the 50-day moving average and -22.61% away from the 200-day moving average. The market capitalization of the company currently stands at $207.34M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On August 28, 2023, H.C. Wainwright Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $3.75, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Dahan Michel, SVP, Chief Operating Officer sold 34,840 shares of the company’s stock on May 13 ’24. The stock was sold for $43,898 at an average price of $1.26. Upon completion of the transaction, the SVP, Chief Operating Officer now directly owns 672,092 shares in the company, valued at $0.67 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 13 ’24, SVP, Chief Legal Officer Hadas Nicole R. sold 12,016 shares of the business’s stock. A total of $15,140 was realized by selling the stock at an average price of $1.26. This leaves the insider owning 651,243 shares of the company worth $0.64 million. A total of 8.46% of the company’s stock is owned by insiders.
During the past 12 months, Akebia Therapeutics Inc. has had a low of $0.78 and a high of $2.48. The fifty day moving average price for AKBA is $1.1745 and a two-hundred day moving average price translates $1.276635 for the stock.
The latest earnings results from Akebia Therapeutics Inc. (NASDAQ: AKBA) was released for 2024-03-31. The net profit margin was -22.98% and return on equity was -554.87% for AKBA. The company reported revenue of $32.61 million for the quarter, compared to $40.01 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -18.49 percent.
